Literature DB >> 17985129

PET/CT imaging of recurrent prostate cancer.

B Scher1, M Seitz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 17985129     DOI： 10.1007/s00259-007-0633-9

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  36 in total

1.  11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse.

Authors:  Nobuyuki Oyama; Tom R Miller; Farrokh Dehdashti; Barry A Siegel; Keith C Fischer; Jeff M Michalski; Adam S Kibel; Gerald L Andriole; Joel Picus; Michael J Welch
Journal:  J Nucl Med       Date:  2003-04       Impact factor: 10.057

2.  Development of (18)F-fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging.

Authors:  Toshihiko Hara; Noboru Kosaka; Hiroichi Kishi
Journal:  J Nucl Med       Date:  2002-02       Impact factor: 10.057

3.  Fluorocholine PET/CT in patients with prostate cancer: initial experience.

Authors:  Daniel T Schmid; Hubert John; Roland Zweifel; Tibor Cservenyak; Gerrit Westera; Gerhard W Goerres; Gustav K von Schulthess; Thomas F Hany
Journal:  Radiology       Date:  2005-05       Impact factor: 11.105

4.  Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml?

Authors:  Martin Heinisch; Albert Dirisamer; Wolfgang Loidl; Franz Stoiber; Bernhard Gruy; Silke Haim; Werner Langsteger
Journal:  Mol Imaging Biol       Date:  2006 Jan-Feb       Impact factor: 3.488

5.  Detection of pelvic lymph node metastases in patients with clinically localized prostate cancer: comparison of [18F]fluorocholine positron emission tomography-computerized tomography and laparoscopic radioisotope guided sentinel lymph node dissection.

Authors:  Axel Häcker; Stefan Jeschke; Karl Leeb; Kurt Prammer; Josef Ziegerhofer; Wolfgang Sega; Werner Langsteger; Guenter Janetschek
Journal:  J Urol       Date:  2006-11       Impact factor: 7.450

6.  The value of serial prostate specific antigen determinations 5 years after radiotherapy: steeply increasing values characterize 80% of patients.

Authors:  T A Stamey; M K Ferrari; H P Schmid
Journal:  J Urol       Date:  1993-12       Impact factor: 7.450

7.  11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer.

Authors:  I J de Jong; J Pruim; P H Elsinga; W Vaalburg; H J A Mensink
Journal:  Eur Urol       Date:  2003-07       Impact factor: 20.096

8.  Predictors of metastatic disease in men with biochemical failure following radical prostatectomy.

Authors:  Onisuru T Okotie; William J Aronson; Jeff A Wieder; Yen Liao; Fred Dorey; Jean B DeKERNION; Stephen J Freedland
Journal:  J Urol       Date:  2004-06       Impact factor: 7.450

9.  Evaluation of the potential of diffusion-weighted imaging in prostate cancer detection.

Authors:  V A Morgan; S Kyriazi; S E Ashley; N M DeSouza
Journal:  Acta Radiol       Date:  2007-07       Impact factor: 1.990

10.  [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients.

Authors:  Marino Cimitan; Roberto Bortolus; Sandro Morassut; Vincenzo Canzonieri; Antonio Garbeglio; Tanja Baresic; Eugenio Borsatti; Annalisa Drigo; Mauro G Trovò
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07-25       Impact factor: 10.057
View more
  2 in total

1.  [Imaging diagnostics of advanced prostate cancer].

Authors:  A Kretschmer; M Seitz; A Graser; C G Stief; D Tilki
Journal:  Urologe A       Date:  2013-04       Impact factor: 0.639

2.  PSMA as a target for radiolabelled small molecules.

Authors:  Matthias Eder; Michael Eisenhut; John Babich; Uwe Haberkorn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-06       Impact factor: 9.236
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.